(CercleFinance.com) – Bristol Myers Squibb announces that the Phase 3 CheckMate-73L trial did not meet its primary endpoint of progression-free survival in non-small cell lung cancer (NSCLC) unresectable and locally advanced stage III.
The pharmaceutical company recalls that CheckMate -73L evaluated its Opdivo with concomitant chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy compared to CCRT followed by durvalumab in patients with unresectable stage III NSCLC.
Adverse effects were generally consistent with the known profiles of each component of the regimen. Bristol Myers will conduct a comprehensive evaluation of the data and work with researchers to share the results with the scientific community.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
